TherapeuticsMD Announces Submission Of Add'l Safety Information For TX-004HR NDA, Scheduled Meeting With FDA For 11/3/17; Co. Expects To Learn Then If Add'l Data Addresses Concerns In Previously Issued CRL
Hal Lindon